• 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"
쳇봇 이모티콘
ScienceON 챗봇입니다.
궁금한 것은 저에게 물어봐주세요.

논문 상세정보


The synthesis and structure-activity relationships of a novel series of substituted quercetins that activates peroxisome proliferator-activated receptor gamma ($PPAR{\gamma}$) are reported. The $PPAR{\gamma}$ agonistic activity of the most potent compound in this series is comparable to that of the thiazolidinedione-based antidiabetic drugs currently in clinical use.

저자의 다른 논문

참고문헌 (20)

  1. Brownlee, M., Biochemistry and molecular cell biology of diabetic complications. Nature, 414, 813-820 (2001) 
  2. Fujita, T., Sugiyama, Y., Taketomi, S., Sohda, T., Kawamatsu, Y., Iwatsuka, H., and Suzuoki, Z., Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy) benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes, 32, 804-810 (1983). 
  3. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., and Kliewer, S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem., 270, 12953-12956 (1995) 
  4. Marcus, A. O., Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2. Diabetes Technol. Ther., 2, 275-285 (2000b) 
  5. Nuraliev, Iu. N. and Avezov, G. A., The efficacy of quercetin in alloxan diabetes. Eks. Klin. Farmakol., 55, 42-44 (1992) 
  6. Shetty, A. K., Rashmi, R., Rajan, M. G. R., Sambaiah, K., and Salimath, P. V., Nutrition Research (New York, NY, United States), 24, 373-381 (2004) 
  7. Morral, N., Novel targets and therapeutic strategies for type 2 diabetes. Trends in endocrinology and metabolism, 14, 169-175 (2003) 
  8. Varma, S. D., Mizuno, A., and Kinoshita, J. H., Diabetic cataracts and flavonoids. Science, 195, 205-206 (1977) 
  9. Nuss, J. M. and Wagman, A. S., Recent advances in therapeutic approaches to type 2 diabetes, In Annual Reports in Medicinal Chemistry, Doherty, A. M., Ed., Academic Press, San Diego, CA, 35, 211-220 (2000) 
  10. Satyanarayana, N. and Periasamy, M., Hydroboration or hydrogenation of alkenes with cobalt(II) chloride-sodium borohydride. Tetrahedron Lett., 25, 2501-2504 (1984) 
  11. Clark, D. A., Goldstein, S. W., Volkmann, R. A., and Eggler, J. F., Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents. J. Med.Chem., 34, 319-325 (1991) 
  12. Shinkai, H., Onogi, S., Tanaka, M., Shibata, T., Iwao, M., Wakitani, K., and Uchida, I., Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents. J. Med. Chem., 41, 1927-1933 (1998) 
  13. Buckle, D. R., Cantello, B. C. C., Cawthorne, M. A., Coyle, P. J., Dean, D. K., Faller, A., Haigh, D., Hindley, R. M., Jefcott, L. J., Lister, C. A., Pinto, I. L., Rami, H. K., Smith, D. G., and Smith, S. A., Non-thiazolidinedione antihyperglycemic agents. 2: alpha-carbon substituted beta-phenylpropanoic acids. Bioorg. Med. Chem. Lett., 6, 2127-2130 (1996) 
  14. DeFronzo, R. A., Bonadonna, R. C., and Ferrannini, E., Pathogenesis of NIDDM. A balanced overview. Diabetes Care, 15, 318-368 (1992) 
  15. Marcus, A. O., Safety of drugs commonly used to treat hypertension, dyslipidemia, and type 2 diabetes (the metabolic syndrome): part 1. Diabetes Technol. Ther., 2, 101-110 (2000a) 
  16. Momose, Y., Meguro, K., Ikeda, H., Hatanka, C., Oi, S., and Sohda, T., Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds. Chem. Pharm. Bull., 39, 1440-1445 (1991) 
  17. Porte, D., Jr. and Schwartz, M. W., Diabetes complications: why is glucose potentially toxic? Science, 272, 699-700 (1996) 
  18. Sohda, T., Mizuno, K., Imamiya, E., Sugiyama, Y., Fujita, T., and Kawamatsu, Y., Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4- dione (ADD-3878) and its derivatives. Chem. Pharm. Bull., 30, 3580-3600 (1982) 
  19. Cantello, B. C., Cawthorne, M. A., Haigh, D., Hindley, R. M., Smith, S. A., and Thurlby, P., [omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem., 37, 3977-3985 (1994). 
  20. Zimmet, P., Alberti, K. G. M. N., and Shaw, J., Global and societal implications of the diabetes epidemic. Nature, 414, 782 -787(2001) 

이 논문을 인용한 문헌 (0)

  1. 이 논문을 인용한 문헌 없음


원문 PDF 다운로드

  • ScienceON :

원문 URL 링크

원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다. (원문복사서비스 안내 바로 가기)

상세조회 0건 원문조회 0건

DOI 인용 스타일